Astellas Pharma to transfer Intal rights to Sanofi-aventis
Astellas Pharma is set to transfer the rights to distribute the anti-allergic drug Intal (sodium cromoglycate) to Sanofi-aventis effective on 1 January 2011.
Astellas Pharma is also expected to transfer the manufacturing and marketing approval for all Intal products to Sanofi-aventis as of 1 October 2010.
Intal is a chemical mediator release inhibitor discovered by the British company Fisons (currently Sanofi-aventis Group) and has seven different formulations.
Intal is indicated for a wide range of allergic diseases, such as allergic conjunctivitis/vernal conjunctivitis, allergic rhinitis, atopic dermatitis caused by food allergies and bronchial asthma.
Related Insight
Suppliers Directory
Hudson Robotics - Lab Automation Solutions.
We produce robots that allow users to easily turn microplate readers into automated screening systems. We have microplate movement and storage systems, as well as liquid handling solutions. We also offer complete workcells for biological research and drug discovery, in which our products are integrated with third party equipment to solve complex laboratory protocols.
Production & Manufacturing > Manufacturing > Suppliers
Tablet Hardness Testers
Dr. Schleuniger Pharmatron provides complete tablet testing solutions and specializes in tablet hardness testers and tablet disintegration testers. With a proven track record of more than 15’000 testers, Dr. Schleuniger Pharmatron physical test equipment for solid dosage forms is used in research laboratories, quality control departments and in automatic IPC (in-process control) of pharmaceutical companies all over the world.
Production & Manufacturing > Manufacturing > Suppliers
Sotax - Solutions for Pharmaceutical Testing
SOTAX, founded in 1973 in Switzerland, is a fast-growing group leader in providing high-quality dissolution testing systems, composite assay and content uniformity workstations and physical tablet testing instruments for the pharmaceutical industry throughout the world.
Production & Manufacturing > Manufacturing > Suppliers
Bachem - Process Development and Manufacturing of Peptides and Complex Organic Molecules as APIs
Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialised in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes.
Production & Manufacturing > Manufacturing > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Manufacturing Intelligence
Quality By Design: The Automated Pharmaceutical Assay
Published by Sotax
Production & Manufacturing > Manufacturing > White Papers
Evidence Investigator
Published by Randox
Production & Manufacturing > Manufacturing > White Papers
GRACO's New Hydra-Clean
Published by GRACO PBR
Production & Manufacturing > Manufacturing > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.